nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—ESR2—seminiferous tubule of testis—testicular cancer	0.115	0.356	CbGeAlD
Fulvestrant—ESR2—Ovarian Infertility Genes—DAZL—testicular cancer	0.0406	0.393	CbGpPWpGaD
Fulvestrant—EPHX2—seminal vesicle—testicular cancer	0.0257	0.0794	CbGeAlD
Fulvestrant—ESRRA—seminal vesicle—testicular cancer	0.0225	0.0696	CbGeAlD
Fulvestrant—NR1H4—female gonad—testicular cancer	0.0173	0.0534	CbGeAlD
Fulvestrant—ESRRA—Preimplantation Embryo—DNMT3L—testicular cancer	0.0158	0.153	CbGpPWpGaD
Fulvestrant—EPHX2—female gonad—testicular cancer	0.0151	0.0466	CbGeAlD
Fulvestrant—EPHX2—testis—testicular cancer	0.0134	0.0414	CbGeAlD
Fulvestrant—ESRRA—female gonad—testicular cancer	0.0132	0.0409	CbGeAlD
Fulvestrant—ESRRA—testis—testicular cancer	0.0117	0.0362	CbGeAlD
Fulvestrant—NR1H4—lymph node—testicular cancer	0.0111	0.0343	CbGeAlD
Fulvestrant—EPHX2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.0106	0.103	CbGpPWpGaD
Fulvestrant—ESR1—embryo—testicular cancer	0.00986	0.0304	CbGeAlD
Fulvestrant—ESR2—gonad—testicular cancer	0.00977	0.0302	CbGeAlD
Fulvestrant—EPHX2—lymph node—testicular cancer	0.00971	0.03	CbGeAlD
Fulvestrant—ESRRA—lymph node—testicular cancer	0.00851	0.0263	CbGeAlD
Fulvestrant—ESR2—female gonad—testicular cancer	0.00794	0.0245	CbGeAlD
Fulvestrant—ESR2—testis—testicular cancer	0.00704	0.0217	CbGeAlD
Fulvestrant—ESR1—gonad—testicular cancer	0.00669	0.0207	CbGeAlD
Fulvestrant—ESR1—female gonad—testicular cancer	0.00544	0.0168	CbGeAlD
Fulvestrant—ESR2—lymph node—testicular cancer	0.0051	0.0158	CbGeAlD
Fulvestrant—ESR1—testis—testicular cancer	0.00482	0.0149	CbGeAlD
Fulvestrant—ESR1—lymph node—testicular cancer	0.0035	0.0108	CbGeAlD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00292	0.0283	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—MMP2—testicular cancer	0.00258	0.025	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00233	0.0225	CbGpPWpGaD
Fulvestrant—NR1H4—Biological oxidations—HPGDS—testicular cancer	0.00231	0.0224	CbGpPWpGaD
Fulvestrant—ESR1—LKB1 signaling events—STK11—testicular cancer	0.00224	0.0217	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00185	0.0179	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.00152	0.0147	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—DNMT3L—testicular cancer	0.00145	0.0141	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.00135	0.013	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Dactinomycin—testicular cancer	0.0013	0.00228	CcSEcCtD
Fulvestrant—Dyspnoea—Ifosfamide—testicular cancer	0.0013	0.00227	CcSEcCtD
Fulvestrant—Hot flush—Doxorubicin—testicular cancer	0.0013	0.00227	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—MMP2—testicular cancer	0.0013	0.0126	CbGpPWpGaD
Fulvestrant—Menopausal symptoms—Doxorubicin—testicular cancer	0.00129	0.00225	CcSEcCtD
Fulvestrant—Vomiting—Vinblastine—testicular cancer	0.00129	0.00225	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—MMP2—testicular cancer	0.00128	0.0124	CbGpPWpGaD
Fulvestrant—Breast disorder—Methotrexate—testicular cancer	0.00127	0.00222	CcSEcCtD
Fulvestrant—Vertigo—Etoposide—testicular cancer	0.00127	0.00222	CcSEcCtD
Fulvestrant—Decreased appetite—Ifosfamide—testicular cancer	0.00127	0.00222	CcSEcCtD
Fulvestrant—Headache—Vinblastine—testicular cancer	0.00127	0.00221	CcSEcCtD
Fulvestrant—Leukopenia—Etoposide—testicular cancer	0.00127	0.00221	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00126	0.0022	CcSEcCtD
Fulvestrant—Abdominal pain—Dactinomycin—testicular cancer	0.00126	0.0022	CcSEcCtD
Fulvestrant—Body temperature increased—Dactinomycin—testicular cancer	0.00126	0.0022	CcSEcCtD
Fulvestrant—Fatigue—Ifosfamide—testicular cancer	0.00126	0.0022	CcSEcCtD
Fulvestrant—Hypersensitivity—Bleomycin—testicular cancer	0.00126	0.0022	CcSEcCtD
Fulvestrant—Infection—Cisplatin—testicular cancer	0.00125	0.00219	CcSEcCtD
Fulvestrant—Constipation—Ifosfamide—testicular cancer	0.00125	0.00218	CcSEcCtD
Fulvestrant—Pain—Ifosfamide—testicular cancer	0.00125	0.00218	CcSEcCtD
Fulvestrant—Nervous system disorder—Cisplatin—testicular cancer	0.00124	0.00216	CcSEcCtD
Fulvestrant—Cough—Etoposide—testicular cancer	0.00123	0.00215	CcSEcCtD
Fulvestrant—Asthenia—Bleomycin—testicular cancer	0.00123	0.00214	CcSEcCtD
Fulvestrant—Skin disorder—Cisplatin—testicular cancer	0.00122	0.00214	CcSEcCtD
Fulvestrant—Pain in extremity—Doxorubicin—testicular cancer	0.00122	0.00213	CcSEcCtD
Fulvestrant—Hyperhidrosis—Cisplatin—testicular cancer	0.00122	0.00213	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.00122	0.0118	CbGpPWpGaD
Fulvestrant—Pruritus—Bleomycin—testicular cancer	0.00121	0.00211	CcSEcCtD
Fulvestrant—Chest pain—Etoposide—testicular cancer	0.0012	0.0021	CcSEcCtD
Fulvestrant—Nausea—Vinblastine—testicular cancer	0.0012	0.0021	CcSEcCtD
Fulvestrant—Anorexia—Cisplatin—testicular cancer	0.0012	0.0021	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.0012	0.00209	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Ifosfamide—testicular cancer	0.0012	0.00209	CcSEcCtD
Fulvestrant—Breast disorder—Epirubicin—testicular cancer	0.00119	0.00208	CcSEcCtD
Fulvestrant—Hypersensitivity—Dactinomycin—testicular cancer	0.00118	0.00205	CcSEcCtD
Fulvestrant—Urticaria—Ifosfamide—testicular cancer	0.00116	0.00203	CcSEcCtD
Fulvestrant—Body temperature increased—Ifosfamide—testicular cancer	0.00116	0.00202	CcSEcCtD
Fulvestrant—Abdominal pain—Ifosfamide—testicular cancer	0.00116	0.00202	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00115	0.002	CcSEcCtD
Fulvestrant—Infection—Etoposide—testicular cancer	0.00115	0.002	CcSEcCtD
Fulvestrant—Asthenia—Dactinomycin—testicular cancer	0.00114	0.002	CcSEcCtD
Fulvestrant—Influenza—Epirubicin—testicular cancer	0.00114	0.00199	CcSEcCtD
Fulvestrant—Paraesthesia—Cisplatin—testicular cancer	0.00113	0.00198	CcSEcCtD
Fulvestrant—Dyspnoea—Cisplatin—testicular cancer	0.00112	0.00196	CcSEcCtD
Fulvestrant—Skin disorder—Etoposide—testicular cancer	0.00112	0.00196	CcSEcCtD
Fulvestrant—Hyperhidrosis—Etoposide—testicular cancer	0.00112	0.00195	CcSEcCtD
Fulvestrant—Breast disorder—Doxorubicin—testicular cancer	0.0011	0.00192	CcSEcCtD
Fulvestrant—Anorexia—Etoposide—testicular cancer	0.0011	0.00192	CcSEcCtD
Fulvestrant—Decreased appetite—Cisplatin—testicular cancer	0.0011	0.00191	CcSEcCtD
Fulvestrant—Diarrhoea—Dactinomycin—testicular cancer	0.00109	0.00191	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00109	0.0019	CcSEcCtD
Fulvestrant—Vomiting—Bleomycin—testicular cancer	0.00109	0.0019	CcSEcCtD
Fulvestrant—Infestation NOS—Methotrexate—testicular cancer	0.00108	0.00189	CcSEcCtD
Fulvestrant—Infestation—Methotrexate—testicular cancer	0.00108	0.00189	CcSEcCtD
Fulvestrant—Depression—Methotrexate—testicular cancer	0.00108	0.00189	CcSEcCtD
Fulvestrant—Rash—Bleomycin—testicular cancer	0.00108	0.00188	CcSEcCtD
Fulvestrant—Pain—Cisplatin—testicular cancer	0.00108	0.00188	CcSEcCtD
Fulvestrant—Dermatitis—Bleomycin—testicular cancer	0.00108	0.00188	CcSEcCtD
Fulvestrant—Hypersensitivity—Ifosfamide—testicular cancer	0.00108	0.00188	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—DNMT3L—testicular cancer	0.00106	0.0103	CbGpPWpGaD
Fulvestrant—Influenza—Doxorubicin—testicular cancer	0.00105	0.00184	CcSEcCtD
Fulvestrant—Asthenia—Ifosfamide—testicular cancer	0.00105	0.00183	CcSEcCtD
Fulvestrant—Sweating—Methotrexate—testicular cancer	0.00104	0.00181	CcSEcCtD
Fulvestrant—Paraesthesia—Etoposide—testicular cancer	0.00104	0.00181	CcSEcCtD
Fulvestrant—Pruritus—Ifosfamide—testicular cancer	0.00103	0.00181	CcSEcCtD
Fulvestrant—Dyspnoea—Etoposide—testicular cancer	0.00103	0.0018	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Methotrexate—testicular cancer	0.00103	0.00179	CcSEcCtD
Fulvestrant—Nausea—Bleomycin—testicular cancer	0.00102	0.00177	CcSEcCtD
Fulvestrant—Infestation—Epirubicin—testicular cancer	0.00101	0.00177	CcSEcCtD
Fulvestrant—Infestation NOS—Epirubicin—testicular cancer	0.00101	0.00177	CcSEcCtD
Fulvestrant—Vomiting—Dactinomycin—testicular cancer	0.00101	0.00177	CcSEcCtD
Fulvestrant—Rash—Dactinomycin—testicular cancer	0.00101	0.00176	CcSEcCtD
Fulvestrant—Decreased appetite—Etoposide—testicular cancer	0.001	0.00175	CcSEcCtD
Fulvestrant—Diarrhoea—Ifosfamide—testicular cancer	0.001	0.00175	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Etoposide—testicular cancer	0.000997	0.00174	CcSEcCtD
Fulvestrant—Body temperature increased—Cisplatin—testicular cancer	0.000996	0.00174	CcSEcCtD
Fulvestrant—Fatigue—Etoposide—testicular cancer	0.000995	0.00174	CcSEcCtD
Fulvestrant—Constipation—Etoposide—testicular cancer	0.000987	0.00172	CcSEcCtD
Fulvestrant—Pain—Etoposide—testicular cancer	0.000987	0.00172	CcSEcCtD
Fulvestrant—Urinary tract infection—Epirubicin—testicular cancer	0.000986	0.00172	CcSEcCtD
Fulvestrant—Haemoglobin—Methotrexate—testicular cancer	0.000978	0.00171	CcSEcCtD
Fulvestrant—Haemorrhage—Methotrexate—testicular cancer	0.000973	0.0017	CcSEcCtD
Fulvestrant—Hepatitis—Methotrexate—testicular cancer	0.000973	0.0017	CcSEcCtD
Fulvestrant—Sweating—Epirubicin—testicular cancer	0.000973	0.0017	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—MMP2—testicular cancer	0.000972	0.00941	CbGpPWpGaD
Fulvestrant—Dizziness—Ifosfamide—testicular cancer	0.000967	0.00169	CcSEcCtD
Fulvestrant—Pharyngitis—Methotrexate—testicular cancer	0.000966	0.00169	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Epirubicin—testicular cancer	0.00096	0.00168	CcSEcCtD
Fulvestrant—Nausea—Dactinomycin—testicular cancer	0.000947	0.00165	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Etoposide—testicular cancer	0.000944	0.00165	CcSEcCtD
Fulvestrant—Infestation—Doxorubicin—testicular cancer	0.000939	0.00164	CcSEcCtD
Fulvestrant—Infestation NOS—Doxorubicin—testicular cancer	0.000939	0.00164	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000935	0.00905	CbGpPWpGaD
Fulvestrant—Vomiting—Ifosfamide—testicular cancer	0.000929	0.00162	CcSEcCtD
Fulvestrant—Hypersensitivity—Cisplatin—testicular cancer	0.000928	0.00162	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—DNMT3L—testicular cancer	0.000926	0.00896	CbGpPWpGaD
Fulvestrant—Rash—Ifosfamide—testicular cancer	0.000922	0.00161	CcSEcCtD
Fulvestrant—Dermatitis—Ifosfamide—testicular cancer	0.000921	0.00161	CcSEcCtD
Fulvestrant—Urticaria—Etoposide—testicular cancer	0.000917	0.0016	CcSEcCtD
Fulvestrant—Haemoglobin—Epirubicin—testicular cancer	0.000915	0.0016	CcSEcCtD
Fulvestrant—Abdominal pain—Etoposide—testicular cancer	0.000913	0.00159	CcSEcCtD
Fulvestrant—Body temperature increased—Etoposide—testicular cancer	0.000913	0.00159	CcSEcCtD
Fulvestrant—Urinary tract infection—Doxorubicin—testicular cancer	0.000913	0.00159	CcSEcCtD
Fulvestrant—Hepatitis—Epirubicin—testicular cancer	0.000911	0.00159	CcSEcCtD
Fulvestrant—Haemorrhage—Epirubicin—testicular cancer	0.000911	0.00159	CcSEcCtD
Fulvestrant—Asthenia—Cisplatin—testicular cancer	0.000904	0.00158	CcSEcCtD
Fulvestrant—Pharyngitis—Epirubicin—testicular cancer	0.000904	0.00158	CcSEcCtD
Fulvestrant—Sweating—Doxorubicin—testicular cancer	0.0009	0.00157	CcSEcCtD
Fulvestrant—Oedema peripheral—Epirubicin—testicular cancer	0.000897	0.00157	CcSEcCtD
Fulvestrant—Connective tissue disorder—Epirubicin—testicular cancer	0.000895	0.00156	CcSEcCtD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000889	0.0086	CbGpPWpGaD
Fulvestrant—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000888	0.00155	CcSEcCtD
Fulvestrant—Angiopathy—Methotrexate—testicular cancer	0.000883	0.00154	CcSEcCtD
Fulvestrant—Immune system disorder—Methotrexate—testicular cancer	0.000879	0.00153	CcSEcCtD
Fulvestrant—Nausea—Ifosfamide—testicular cancer	0.000868	0.00152	CcSEcCtD
Fulvestrant—Diarrhoea—Cisplatin—testicular cancer	0.000862	0.00151	CcSEcCtD
Fulvestrant—Hypersensitivity—Etoposide—testicular cancer	0.000851	0.00148	CcSEcCtD
Fulvestrant—Malnutrition—Methotrexate—testicular cancer	0.000847	0.00148	CcSEcCtD
Fulvestrant—Haemoglobin—Doxorubicin—testicular cancer	0.000847	0.00148	CcSEcCtD
Fulvestrant—Hepatitis—Doxorubicin—testicular cancer	0.000843	0.00147	CcSEcCtD
Fulvestrant—Haemorrhage—Doxorubicin—testicular cancer	0.000843	0.00147	CcSEcCtD
Fulvestrant—Pharyngitis—Doxorubicin—testicular cancer	0.000836	0.00146	CcSEcCtD
Fulvestrant—Oedema peripheral—Doxorubicin—testicular cancer	0.00083	0.00145	CcSEcCtD
Fulvestrant—Asthenia—Etoposide—testicular cancer	0.000828	0.00145	CcSEcCtD
Fulvestrant—Connective tissue disorder—Doxorubicin—testicular cancer	0.000828	0.00145	CcSEcCtD
Fulvestrant—Angiopathy—Epirubicin—testicular cancer	0.000826	0.00144	CcSEcCtD
Fulvestrant—Immune system disorder—Epirubicin—testicular cancer	0.000823	0.00144	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.00082	0.00793	CbGpPWpGaD
Fulvestrant—Back pain—Methotrexate—testicular cancer	0.00082	0.00143	CcSEcCtD
Fulvestrant—Pruritus—Etoposide—testicular cancer	0.000817	0.00143	CcSEcCtD
Fulvestrant—Vomiting—Cisplatin—testicular cancer	0.000801	0.0014	CcSEcCtD
Fulvestrant—Rash—Cisplatin—testicular cancer	0.000795	0.00139	CcSEcCtD
Fulvestrant—Dermatitis—Cisplatin—testicular cancer	0.000794	0.00139	CcSEcCtD
Fulvestrant—Malnutrition—Epirubicin—testicular cancer	0.000793	0.00138	CcSEcCtD
Fulvestrant—Diarrhoea—Etoposide—testicular cancer	0.00079	0.00138	CcSEcCtD
Fulvestrant—Anaemia—Methotrexate—testicular cancer	0.000783	0.00137	CcSEcCtD
Fulvestrant—Back pain—Epirubicin—testicular cancer	0.000767	0.00134	CcSEcCtD
Fulvestrant—Angiopathy—Doxorubicin—testicular cancer	0.000765	0.00133	CcSEcCtD
Fulvestrant—Dizziness—Etoposide—testicular cancer	0.000763	0.00133	CcSEcCtD
Fulvestrant—Immune system disorder—Doxorubicin—testicular cancer	0.000761	0.00133	CcSEcCtD
Fulvestrant—Vertigo—Methotrexate—testicular cancer	0.000761	0.00133	CcSEcCtD
Fulvestrant—Leukopenia—Methotrexate—testicular cancer	0.000758	0.00132	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—KITLG—testicular cancer	0.000754	0.0073	CbGpPWpGaD
Fulvestrant—Nausea—Cisplatin—testicular cancer	0.000749	0.00131	CcSEcCtD
Fulvestrant—Cough—Methotrexate—testicular cancer	0.000739	0.00129	CcSEcCtD
Fulvestrant—Vomiting—Etoposide—testicular cancer	0.000734	0.00128	CcSEcCtD
Fulvestrant—Malnutrition—Doxorubicin—testicular cancer	0.000734	0.00128	CcSEcCtD
Fulvestrant—Anaemia—Epirubicin—testicular cancer	0.000733	0.00128	CcSEcCtD
Fulvestrant—Rash—Etoposide—testicular cancer	0.000728	0.00127	CcSEcCtD
Fulvestrant—Dermatitis—Etoposide—testicular cancer	0.000727	0.00127	CcSEcCtD
Fulvestrant—Headache—Etoposide—testicular cancer	0.000723	0.00126	CcSEcCtD
Fulvestrant—Arthralgia—Methotrexate—testicular cancer	0.000721	0.00126	CcSEcCtD
Fulvestrant—Chest pain—Methotrexate—testicular cancer	0.000721	0.00126	CcSEcCtD
Fulvestrant—Myalgia—Methotrexate—testicular cancer	0.000721	0.00126	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000716	0.00125	CcSEcCtD
Fulvestrant—Vertigo—Epirubicin—testicular cancer	0.000712	0.00124	CcSEcCtD
Fulvestrant—Leukopenia—Epirubicin—testicular cancer	0.00071	0.00124	CcSEcCtD
Fulvestrant—Back pain—Doxorubicin—testicular cancer	0.00071	0.00124	CcSEcCtD
Fulvestrant—Cough—Epirubicin—testicular cancer	0.000692	0.00121	CcSEcCtD
Fulvestrant—Infection—Methotrexate—testicular cancer	0.000687	0.0012	CcSEcCtD
Fulvestrant—Nausea—Etoposide—testicular cancer	0.000686	0.0012	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000679	0.00657	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Methotrexate—testicular cancer	0.000678	0.00118	CcSEcCtD
Fulvestrant—Anaemia—Doxorubicin—testicular cancer	0.000678	0.00118	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—HPGDS—testicular cancer	0.000678	0.00656	CbGpPWpGaD
Fulvestrant—Arthralgia—Epirubicin—testicular cancer	0.000675	0.00118	CcSEcCtD
Fulvestrant—Chest pain—Epirubicin—testicular cancer	0.000675	0.00118	CcSEcCtD
Fulvestrant—Myalgia—Epirubicin—testicular cancer	0.000675	0.00118	CcSEcCtD
Fulvestrant—Anxiety—Epirubicin—testicular cancer	0.000673	0.00117	CcSEcCtD
Fulvestrant—Skin disorder—Methotrexate—testicular cancer	0.000672	0.00117	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00067	0.00117	CcSEcCtD
Fulvestrant—Hyperhidrosis—Methotrexate—testicular cancer	0.000668	0.00117	CcSEcCtD
Fulvestrant—Vertigo—Doxorubicin—testicular cancer	0.000659	0.00115	CcSEcCtD
Fulvestrant—Anorexia—Methotrexate—testicular cancer	0.000659	0.00115	CcSEcCtD
Fulvestrant—Leukopenia—Doxorubicin—testicular cancer	0.000657	0.00115	CcSEcCtD
Fulvestrant—Infection—Epirubicin—testicular cancer	0.000643	0.00112	CcSEcCtD
Fulvestrant—Cough—Doxorubicin—testicular cancer	0.00064	0.00112	CcSEcCtD
Fulvestrant—Nervous system disorder—Epirubicin—testicular cancer	0.000635	0.00111	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00063	0.0011	CcSEcCtD
Fulvestrant—Skin disorder—Epirubicin—testicular cancer	0.000629	0.0011	CcSEcCtD
Fulvestrant—Hyperhidrosis—Epirubicin—testicular cancer	0.000626	0.00109	CcSEcCtD
Fulvestrant—Insomnia—Methotrexate—testicular cancer	0.000625	0.00109	CcSEcCtD
Fulvestrant—Chest pain—Doxorubicin—testicular cancer	0.000625	0.00109	CcSEcCtD
Fulvestrant—Arthralgia—Doxorubicin—testicular cancer	0.000625	0.00109	CcSEcCtD
Fulvestrant—Myalgia—Doxorubicin—testicular cancer	0.000625	0.00109	CcSEcCtD
Fulvestrant—Anxiety—Doxorubicin—testicular cancer	0.000622	0.00109	CcSEcCtD
Fulvestrant—Paraesthesia—Methotrexate—testicular cancer	0.000621	0.00108	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00062	0.00108	CcSEcCtD
Fulvestrant—Anorexia—Epirubicin—testicular cancer	0.000617	0.00108	CcSEcCtD
Fulvestrant—Dyspnoea—Methotrexate—testicular cancer	0.000616	0.00108	CcSEcCtD
Fulvestrant—Dyspepsia—Methotrexate—testicular cancer	0.000609	0.00106	CcSEcCtD
Fulvestrant—Decreased appetite—Methotrexate—testicular cancer	0.000601	0.00105	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000597	0.00104	CcSEcCtD
Fulvestrant—Fatigue—Methotrexate—testicular cancer	0.000596	0.00104	CcSEcCtD
Fulvestrant—Infection—Doxorubicin—testicular cancer	0.000595	0.00104	CcSEcCtD
Fulvestrant—Pain—Methotrexate—testicular cancer	0.000591	0.00103	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00059	0.00103	CcSEcCtD
Fulvestrant—Nervous system disorder—Doxorubicin—testicular cancer	0.000587	0.00103	CcSEcCtD
Fulvestrant—Insomnia—Epirubicin—testicular cancer	0.000585	0.00102	CcSEcCtD
Fulvestrant—Skin disorder—Doxorubicin—testicular cancer	0.000582	0.00102	CcSEcCtD
Fulvestrant—Paraesthesia—Epirubicin—testicular cancer	0.000581	0.00101	CcSEcCtD
Fulvestrant—Hyperhidrosis—Doxorubicin—testicular cancer	0.000579	0.00101	CcSEcCtD
Fulvestrant—Dyspnoea—Epirubicin—testicular cancer	0.000577	0.00101	CcSEcCtD
Fulvestrant—Anorexia—Doxorubicin—testicular cancer	0.000571	0.000996	CcSEcCtD
Fulvestrant—Dyspepsia—Epirubicin—testicular cancer	0.00057	0.000994	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Methotrexate—testicular cancer	0.000565	0.000987	CcSEcCtD
Fulvestrant—Decreased appetite—Epirubicin—testicular cancer	0.000563	0.000982	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—FGFR3—testicular cancer	0.000561	0.00543	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000559	0.000975	CcSEcCtD
Fulvestrant—Fatigue—Epirubicin—testicular cancer	0.000558	0.000974	CcSEcCtD
Fulvestrant—Constipation—Epirubicin—testicular cancer	0.000553	0.000966	CcSEcCtD
Fulvestrant—Pain—Epirubicin—testicular cancer	0.000553	0.000966	CcSEcCtD
Fulvestrant—Urticaria—Methotrexate—testicular cancer	0.000549	0.000959	CcSEcCtD
Fulvestrant—Abdominal pain—Methotrexate—testicular cancer	0.000547	0.000954	CcSEcCtD
Fulvestrant—Body temperature increased—Methotrexate—testicular cancer	0.000547	0.000954	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000546	0.000952	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—HPGDS—testicular cancer	0.000542	0.00524	CbGpPWpGaD
Fulvestrant—Insomnia—Doxorubicin—testicular cancer	0.000542	0.000945	CcSEcCtD
Fulvestrant—Paraesthesia—Doxorubicin—testicular cancer	0.000538	0.000939	CcSEcCtD
Fulvestrant—Dyspnoea—Doxorubicin—testicular cancer	0.000534	0.000932	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Epirubicin—testicular cancer	0.000529	0.000924	CcSEcCtD
Fulvestrant—Dyspepsia—Doxorubicin—testicular cancer	0.000527	0.00092	CcSEcCtD
Fulvestrant—Decreased appetite—Doxorubicin—testicular cancer	0.000521	0.000909	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000517	0.000902	CcSEcCtD
Fulvestrant—Fatigue—Doxorubicin—testicular cancer	0.000516	0.000901	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—KIT—testicular cancer	0.000515	0.00498	CbGpPWpGaD
Fulvestrant—Urticaria—Epirubicin—testicular cancer	0.000514	0.000897	CcSEcCtD
Fulvestrant—Pain—Doxorubicin—testicular cancer	0.000512	0.000894	CcSEcCtD
Fulvestrant—Constipation—Doxorubicin—testicular cancer	0.000512	0.000894	CcSEcCtD
Fulvestrant—Abdominal pain—Epirubicin—testicular cancer	0.000512	0.000893	CcSEcCtD
Fulvestrant—Body temperature increased—Epirubicin—testicular cancer	0.000512	0.000893	CcSEcCtD
Fulvestrant—Hypersensitivity—Methotrexate—testicular cancer	0.000509	0.000889	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—H2AFZ—testicular cancer	0.000509	0.00493	CbGpPWpGaD
Fulvestrant—Asthenia—Methotrexate—testicular cancer	0.000496	0.000866	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—STK11—testicular cancer	0.000492	0.00476	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00049	0.000855	CcSEcCtD
Fulvestrant—Pruritus—Methotrexate—testicular cancer	0.000489	0.000854	CcSEcCtD
Fulvestrant—Hypersensitivity—Epirubicin—testicular cancer	0.000477	0.000832	CcSEcCtD
Fulvestrant—Urticaria—Doxorubicin—testicular cancer	0.000476	0.00083	CcSEcCtD
Fulvestrant—Abdominal pain—Doxorubicin—testicular cancer	0.000473	0.000826	CcSEcCtD
Fulvestrant—Body temperature increased—Doxorubicin—testicular cancer	0.000473	0.000826	CcSEcCtD
Fulvestrant—Diarrhoea—Methotrexate—testicular cancer	0.000473	0.000826	CcSEcCtD
Fulvestrant—ESR1—Gene Expression—DNMT3L—testicular cancer	0.000467	0.00452	CbGpPWpGaD
Fulvestrant—Asthenia—Epirubicin—testicular cancer	0.000464	0.000811	CcSEcCtD
Fulvestrant—Pruritus—Epirubicin—testicular cancer	0.000458	0.000799	CcSEcCtD
Fulvestrant—Dizziness—Methotrexate—testicular cancer	0.000457	0.000798	CcSEcCtD
Fulvestrant—Diarrhoea—Epirubicin—testicular cancer	0.000443	0.000773	CcSEcCtD
Fulvestrant—Hypersensitivity—Doxorubicin—testicular cancer	0.000441	0.00077	CcSEcCtD
Fulvestrant—Vomiting—Methotrexate—testicular cancer	0.00044	0.000768	CcSEcCtD
Fulvestrant—Rash—Methotrexate—testicular cancer	0.000436	0.000761	CcSEcCtD
Fulvestrant—Dermatitis—Methotrexate—testicular cancer	0.000436	0.00076	CcSEcCtD
Fulvestrant—Headache—Methotrexate—testicular cancer	0.000433	0.000756	CcSEcCtD
Fulvestrant—Asthenia—Doxorubicin—testicular cancer	0.00043	0.00075	CcSEcCtD
Fulvestrant—Dizziness—Epirubicin—testicular cancer	0.000428	0.000747	CcSEcCtD
Fulvestrant—Pruritus—Doxorubicin—testicular cancer	0.000424	0.00074	CcSEcCtD
Fulvestrant—Vomiting—Epirubicin—testicular cancer	0.000411	0.000718	CcSEcCtD
Fulvestrant—Nausea—Methotrexate—testicular cancer	0.000411	0.000717	CcSEcCtD
Fulvestrant—Diarrhoea—Doxorubicin—testicular cancer	0.00041	0.000715	CcSEcCtD
Fulvestrant—Rash—Epirubicin—testicular cancer	0.000408	0.000712	CcSEcCtD
Fulvestrant—Dermatitis—Epirubicin—testicular cancer	0.000408	0.000712	CcSEcCtD
Fulvestrant—Headache—Epirubicin—testicular cancer	0.000405	0.000708	CcSEcCtD
Fulvestrant—Dizziness—Doxorubicin—testicular cancer	0.000396	0.000691	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—HPGDS—testicular cancer	0.000396	0.00383	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—STK11—testicular cancer	0.000394	0.00381	CbGpPWpGaD
Fulvestrant—Nausea—Epirubicin—testicular cancer	0.000384	0.000671	CcSEcCtD
Fulvestrant—Vomiting—Doxorubicin—testicular cancer	0.000381	0.000665	CcSEcCtD
Fulvestrant—Rash—Doxorubicin—testicular cancer	0.000378	0.000659	CcSEcCtD
Fulvestrant—Dermatitis—Doxorubicin—testicular cancer	0.000377	0.000658	CcSEcCtD
Fulvestrant—Headache—Doxorubicin—testicular cancer	0.000375	0.000655	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—H2AFZ—testicular cancer	0.000372	0.0036	CbGpPWpGaD
Fulvestrant—Nausea—Doxorubicin—testicular cancer	0.000356	0.000621	CcSEcCtD
Fulvestrant—ESR1—Signaling Pathways—INSL3—testicular cancer	0.000332	0.00321	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000331	0.00321	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—H2AFZ—testicular cancer	0.000324	0.00314	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—STK11—testicular cancer	0.000288	0.00278	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—H2AFZ—testicular cancer	0.000163	0.00158	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—H2AFZ—testicular cancer	0.000106	0.00103	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—STK11—testicular cancer	0.000106	0.00102	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KITLG—testicular cancer	9.77e-05	0.000946	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FGFR3—testicular cancer	7.26e-05	0.000703	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KIT—testicular cancer	6.67e-05	0.000645	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—HPGDS—testicular cancer	5.67e-05	0.000548	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—STK11—testicular cancer	4.12e-05	0.000398	CbGpPWpGaD
